홈 > 시장보고서 > 의료기기 > 체외진단

시장보고서

상품코드

1193238

폐암 검진 시장 : 유형별(저선량 CT(LDCT), X선), 연령층별(50세 이상, 50세 미만), 최종 사용자별(병원, 진단 센터, 기타) - 세계 기회 분석 및 산업 예측(2021-2031년)

Lung Cancer Screening Market By Type (Low-dose computed tomography (LDCT), X-ray), By Age group (50 and older, Below 50), By End User (Hospitals, Diagnostic Centers, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031

발행일: 2022년 10월 | 리서치사:

Allied Market Research | 페이지 정보: 영문 271 Pages | 배송안내 : 2-3일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

폐암 검진의 세계 시장은 2021년에 8억 7,959만 달러로, 2022년부터 2031년에 걸쳐 CAGR 7.7%로 성장해, 2031년에는 18억 5,304만 달러에 달할 것으로 예측됩니다.

폐암 검진이란 폐암이 치유될 가능성이 높은 시점에서 증상이 나오기 전에 초기 폐암을 발견하는 방법을 말합니다. 폐암은 폐에서 발생하는 암 중에서 가장 흔한 것입니다. 폐암의 주요 원인은 담배 연기입니다. 종양 세포의 현미경 외관에 따라 소세포 폐암 (SCLC)과 비소 세포 폐암 (NSCLC)으로 분류됩니다. 폐암의 스크리닝 검사로 권장되는 것은 저선량 컴퓨터 단층촬영과 X선 검사입니다.

폐암 검진의 세계 시장의 성장은 주로 세계 각지의 폐암 유병률의 우려할만한 증가, 흡연 인구의 증가, 검진 방법의 기술 혁신에 견인되고 있습니다. 예를 들어, 2020년 미국 임상종양학회(ASCO)는 폐암이 여성과 남성에서 두 번째로 많은 암의 종류라고 말합니다. 또, 폐암을 조기에 발견하기 위한 정부의 대처가 증가하고 있는 것도, 시장의 성장을 뒷받침하고 있습니다.

게다가 폐암의 조기 스크리닝에 대한 의식의 증가와 폐암 발생률의 급증은 효과적인 스크리닝 검사에 대한 수요를 증가시키는 원인이 되고 있습니다. 이러한 요인은 예측 기간 동안 폐암 검진 시장의 성장 기회를 창출할 것으로 예상됩니다.

그러나 신흥국에서 스크리닝 검사의 높은 비용과 스크리닝 기술에 대한 인식 부족은 시장 성장을 방해할 것으로 예상되는 요인이다.

개요
- 시장 규모·예측
병원
- 주요 시장 동향, 성장 요인과 기회
- 시장 규모·예측 : 지역별
- 시장 분석 : 국가별 분석
- 병원 폐암 검진 시장 : 유형별
  - 퍼블릭 시장 규모·예측 : 지역별
  - 민간 시장 규모·예측 : 지역별
진단 센터
- 주요 시장 동향, 성장 요인, 기회
- 시장 규모·예측 : 지역별
- 시장 분석 : 국가별
기타
- 주요 시장 동향, 성장 요인, 기회
- 시장 규모·예측 : 지역별
- 시장 분석 : 국가별

제7장 폐암 검진 시장 : 지역별

개요
- 시장 규모·예측
북미
- 주요 동향과 기회
- 북미 시장 규모·예측 : 유형별
- 북미 시장 규모·예측 : 연령층별
- 북미의 시장 규모·예측 : 엔드유저별
  - 북미의 병원용 폐암 검진 시장 : 유형별
- 북미 시장 규모·예측 : 국가별
  - 미국
  - 캐나다
  - 멕시코
유럽
- 주요 동향과 기회
- 유럽의 시장 규모·예측 : 유형별
- 유럽 시장 규모·예측 : 연령층별
- 유럽 시장 규모·예측 : 최종 사용자별
  - 유럽 병원 폐암 검진 시장 : 유형별
- 유럽 시장 규모·예측 : 국가별
  - 독일
  - 프랑스
  - 영국
  - 이탈리아
  - 스페인
  - 기타 유럽
아시아태평양
- 주요 동향과 기회
- 아시아태평양의 시장 규모·예측 : 유형별
- 아시아태평양의 시장 규모·예측 : 연령층별
- 아시아태평양의 시장 규모·예측 : 최종 사용자별
  - 아시아태평양의 병원용 폐암 검진 시장 : 유형별
- 아시아태평양의 시장 규모·예측 : 국가별
  - 일본
  - 중국
  - 호주
  - 인도
  - 한국
  - 기타 아시아태평양
LAMEA
- 주요 동향과 기회
- LAMEA의 시장 규모·예측 : 유형별
- LAMEA의 시장 규모·예측 : 연령층별
- LAMEA의 시장 규모·예측 : 엔드유저별
  - LAMEA의 병원용 폐암 검진 시장 : 유형별
- LAMEA의 시장 규모·예측 : 국가별
  - 브라질
  - 사우디아라비아
  - 남아프리카 공화국
  - 기타 LAMEA

제8장 기업 정세

소개
주요 성공 전략
주요 10개사의 제품 매핑
경쟁 대시보드
경합의 히트 맵
주요 발전

제9장 기업 프로필

Canon Medical Systems Corporation
Eon Health
FUJIFILM Holdings Corporation
General Electric incorporated(GE Healthcare)
Koninklijke Philips NV
Medtronic plc
Nuance Communications, Inc.
Penrad Technologies Inc
Siemens AG(Siemens Healthineers AG)
Volpara Solutions Limited

ksm 23.03.27

The global lung cancer screening market was valued at $879.59 million in 2021, and is projected to reach $1,853.04 million by 2031, registering a CAGR of 7.7% from 2022 to 2031.

Lung cancer screening refers to methods for detecting early lung cancer before they cause symptoms at a point where they are more likely to be cured. Lung cancer is the most common type of cancer that begins in the lungs. Cigarette smoking is the main cause of lung cancer. Based on the microscopic appearance, the tumor cells are classified into small cell lung cancers (SCLC) and non-small cell lung cancers (NSCLC). The recommended screening test for lung cancer are low-dose computed tomography and X-ray.

The growth of global lung cancer screening market is majorly driven by alarming increase in prevalence of lung cancer across the globe, increase in smoking population, and technological innovations in screening methods. For instance, the American Society of Clinical Oncology (ASCO) in 2020, stated that the lung cancer is the 2nd most common type of cancer in women and men. In addition, rise in efforts taken by government for early stage detection of lung cancer propels the growth of the market.

Furthermore, rise in awareness regarding early stage screening for lung cancer and surge in the incidences of lung cancer are responsible to increase the demand for effective screening tests. These factors are expected to create growth opportunities for the lung cancer screening market during the forecast period.

However, high cost of screening tests and lack of awareness regarding screening techniques in the developing countries are the factors expected to hamper the growth of the market.

The lung cancer screening market is segmented into type, age group, end user, and region. By type, the market is categorized into low-dose computed tomography (LDCT) and X-ray. On the basis of age group, the market is segregated into 50 and older and below 50. By end user, the market is classified into hospitals, diagnostic centers, and others. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the global lung cancer screening market are Canon Medical Systems U.S. Inc., Eon Health, Fujifilm Holdings Corporation, General Electric Company (GE Healthcare), Koninklijke Philips N.V., Medtronic Plc, Microsoft Corporation (Nuance Communications, Inc.), Penrad Technologies Inc., Siemens Ag, and Volpara Solutions Limited.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the lung cancer screening market analysis from 2021 to 2031 to identify the prevailing lung cancer screening market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the lung cancer screening market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global lung cancer screening market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Type

Low-dose computed tomography (LDCT)
X-ray

By Age group

50 and older
Below 50

By End User

Hospitals
- Type
- Public
- Private
Diagnostic Centers
Others

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest Of Europe
Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest Of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest Of LAMEA
Key Market Players
- Canon Medical Systems Corporation
- Eon Health
- FUJIFILM Holdings Corporation
- General Electric incorporated (GE Healthcare)
- Koninklijke Philips N.V.
- Medtronic plc
- Nuance Communications, Inc.
- Penrad Technologies Inc
- Siemens AG (Siemens Healthineers AG)
- Volpara Solutions Limited

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings
- 3.2.1.Top investment pockets
3.3.Porter's five forces analysis
3.4.Top player positioning
3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: LUNG CANCER SCREENING MARKET, BY TYPE

4.1 Overview
- 4.1.1 Market size and forecast
4.2 Low-dose computed tomography (LDCT)
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
4.3 X-ray
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country

CHAPTER 5: LUNG CANCER SCREENING MARKET, BY AGE GROUP

5.1 Overview
- 5.1.1 Market size and forecast
5.2 50 and older
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
5.3 Below 50
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country

CHAPTER 6: LUNG CANCER SCREENING MARKET, BY END USER

6.1 Overview
- 6.1.1 Market size and forecast
6.2 Hospitals
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
- 6.2.4 Hospitals Lung Cancer Screening Market by Type
  - 6.2.4.1 Public Market size and forecast, by region
  - 6.2.4.2 Private Market size and forecast, by region
6.3 Diagnostic Centers
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country
6.4 Others
- 6.4.1 Key market trends, growth factors and opportunities
- 6.4.2 Market size and forecast, by region
- 6.4.3 Market analysis by country

CHAPTER 7: LUNG CANCER SCREENING MARKET, BY REGION

7.1 Overview
- 7.1.1 Market size and forecast
7.2 North America
- 7.2.1 Key trends and opportunities
- 7.2.2 North America Market size and forecast, by Type
- 7.2.3 North America Market size and forecast, by Age group
- 7.2.4 North America Market size and forecast, by End User
  - 7.2.4.1 North America Hospitals Lung Cancer Screening Market by Type
- 7.2.5 North America Market size and forecast, by country
  - 7.2.5.1 U.S.
  - 7.2.5.1.1 Market size and forecast, by Type
  - 7.2.5.1.2 Market size and forecast, by Age group
  - 7.2.5.1.3 Market size and forecast, by End User
  - 7.2.5.2 Canada
  - 7.2.5.2.1 Market size and forecast, by Type
  - 7.2.5.2.2 Market size and forecast, by Age group
  - 7.2.5.2.3 Market size and forecast, by End User
  - 7.2.5.3 Mexico
  - 7.2.5.3.1 Market size and forecast, by Type
  - 7.2.5.3.2 Market size and forecast, by Age group
  - 7.2.5.3.3 Market size and forecast, by End User
7.3 Europe
- 7.3.1 Key trends and opportunities
- 7.3.2 Europe Market size and forecast, by Type
- 7.3.3 Europe Market size and forecast, by Age group
- 7.3.4 Europe Market size and forecast, by End User
  - 7.3.4.1 Europe Hospitals Lung Cancer Screening Market by Type
- 7.3.5 Europe Market size and forecast, by country
  - 7.3.5.1 Germany
  - 7.3.5.1.1 Market size and forecast, by Type
  - 7.3.5.1.2 Market size and forecast, by Age group
  - 7.3.5.1.3 Market size and forecast, by End User
  - 7.3.5.2 France
  - 7.3.5.2.1 Market size and forecast, by Type
  - 7.3.5.2.2 Market size and forecast, by Age group
  - 7.3.5.2.3 Market size and forecast, by End User
  - 7.3.5.3 UK
  - 7.3.5.3.1 Market size and forecast, by Type
  - 7.3.5.3.2 Market size and forecast, by Age group
  - 7.3.5.3.3 Market size and forecast, by End User
  - 7.3.5.4 Italy
  - 7.3.5.4.1 Market size and forecast, by Type
  - 7.3.5.4.2 Market size and forecast, by Age group
  - 7.3.5.4.3 Market size and forecast, by End User
  - 7.3.5.5 Spain
  - 7.3.5.5.1 Market size and forecast, by Type
  - 7.3.5.5.2 Market size and forecast, by Age group
  - 7.3.5.5.3 Market size and forecast, by End User
  - 7.3.5.6 Rest of Europe
  - 7.3.5.6.1 Market size and forecast, by Type
  - 7.3.5.6.2 Market size and forecast, by Age group
  - 7.3.5.6.3 Market size and forecast, by End User
7.4 Asia-Pacific
- 7.4.1 Key trends and opportunities
- 7.4.2 Asia-Pacific Market size and forecast, by Type
- 7.4.3 Asia-Pacific Market size and forecast, by Age group
- 7.4.4 Asia-Pacific Market size and forecast, by End User
  - 7.4.4.1 Asia-Pacific Hospitals Lung Cancer Screening Market by Type
- 7.4.5 Asia-Pacific Market size and forecast, by country
  - 7.4.5.1 Japan
  - 7.4.5.1.1 Market size and forecast, by Type
  - 7.4.5.1.2 Market size and forecast, by Age group
  - 7.4.5.1.3 Market size and forecast, by End User
  - 7.4.5.2 China
  - 7.4.5.2.1 Market size and forecast, by Type
  - 7.4.5.2.2 Market size and forecast, by Age group
  - 7.4.5.2.3 Market size and forecast, by End User
  - 7.4.5.3 Australia
  - 7.4.5.3.1 Market size and forecast, by Type
  - 7.4.5.3.2 Market size and forecast, by Age group
  - 7.4.5.3.3 Market size and forecast, by End User
  - 7.4.5.4 India
  - 7.4.5.4.1 Market size and forecast, by Type
  - 7.4.5.4.2 Market size and forecast, by Age group
  - 7.4.5.4.3 Market size and forecast, by End User
  - 7.4.5.5 South Korea
  - 7.4.5.5.1 Market size and forecast, by Type
  - 7.4.5.5.2 Market size and forecast, by Age group
  - 7.4.5.5.3 Market size and forecast, by End User
  - 7.4.5.6 Rest of Asia-Pacific
  - 7.4.5.6.1 Market size and forecast, by Type
  - 7.4.5.6.2 Market size and forecast, by Age group
  - 7.4.5.6.3 Market size and forecast, by End User
7.5 LAMEA
- 7.5.1 Key trends and opportunities
- 7.5.2 LAMEA Market size and forecast, by Type
- 7.5.3 LAMEA Market size and forecast, by Age group
- 7.5.4 LAMEA Market size and forecast, by End User
  - 7.5.4.1 LAMEA Hospitals Lung Cancer Screening Market by Type
- 7.5.5 LAMEA Market size and forecast, by country
  - 7.5.5.1 Brazil
  - 7.5.5.1.1 Market size and forecast, by Type
  - 7.5.5.1.2 Market size and forecast, by Age group
  - 7.5.5.1.3 Market size and forecast, by End User
  - 7.5.5.2 Saudi Arabia
  - 7.5.5.2.1 Market size and forecast, by Type
  - 7.5.5.2.2 Market size and forecast, by Age group
  - 7.5.5.2.3 Market size and forecast, by End User
  - 7.5.5.3 South Africa
  - 7.5.5.3.1 Market size and forecast, by Type
  - 7.5.5.3.2 Market size and forecast, by Age group
  - 7.5.5.3.3 Market size and forecast, by End User
  - 7.5.5.4 Rest of LAMEA
  - 7.5.5.4.1 Market size and forecast, by Type
  - 7.5.5.4.2 Market size and forecast, by Age group
  - 7.5.5.4.3 Market size and forecast, by End User

CHAPTER 8: COMPANY LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments

CHAPTER 9: COMPANY PROFILES

9.1 Canon Medical Systems Corporation
- 9.1.1 Company overview
- 9.1.2 Company snapshot
- 9.1.3 Operating business segments
- 9.1.4 Product portfolio
- 9.1.5 Business performance
- 9.1.6 Key strategic moves and developments
9.2 Eon Health
- 9.2.1 Company overview
- 9.2.2 Company snapshot
- 9.2.3 Operating business segments
- 9.2.4 Product portfolio
- 9.2.5 Business performance
- 9.2.6 Key strategic moves and developments
9.3 FUJIFILM Holdings Corporation
- 9.3.1 Company overview
- 9.3.2 Company snapshot
- 9.3.3 Operating business segments
- 9.3.4 Product portfolio
- 9.3.5 Business performance
- 9.3.6 Key strategic moves and developments
9.4 General Electric incorporated (GE Healthcare)
- 9.4.1 Company overview
- 9.4.2 Company snapshot
- 9.4.3 Operating business segments
- 9.4.4 Product portfolio
- 9.4.5 Business performance
- 9.4.6 Key strategic moves and developments
9.5 Koninklijke Philips N.V.
- 9.5.1 Company overview
- 9.5.2 Company snapshot
- 9.5.3 Operating business segments
- 9.5.4 Product portfolio
- 9.5.5 Business performance
- 9.5.6 Key strategic moves and developments
9.6 Medtronic plc
- 9.6.1 Company overview
- 9.6.2 Company snapshot
- 9.6.3 Operating business segments
- 9.6.4 Product portfolio
- 9.6.5 Business performance
- 9.6.6 Key strategic moves and developments
9.7 Nuance Communications, Inc.
- 9.7.1 Company overview
- 9.7.2 Company snapshot
- 9.7.3 Operating business segments
- 9.7.4 Product portfolio
- 9.7.5 Business performance
- 9.7.6 Key strategic moves and developments
9.8 Penrad Technologies Inc
- 9.8.1 Company overview
- 9.8.2 Company snapshot
- 9.8.3 Operating business segments
- 9.8.4 Product portfolio
- 9.8.5 Business performance
- 9.8.6 Key strategic moves and developments
9.9 Siemens AG (Siemens Healthineers AG)
- 9.9.1 Company overview
- 9.9.2 Company snapshot
- 9.9.3 Operating business segments
- 9.9.4 Product portfolio
- 9.9.5 Business performance
- 9.9.6 Key strategic moves and developments
9.10 Volpara Solutions Limited
- 9.10.1 Company overview
- 9.10.2 Company snapshot
- 9.10.3 Operating business segments
- 9.10.4 Product portfolio
- 9.10.5 Business performance
- 9.10.6 Key strategic moves and developments

02-2025-2992
(주말 및 공휴일 제외)

라이선스 / 가격

PDF (Single User License)

US $ 5,730

￦ 7,521,000

PDF (5-user License)

US $ 6,450

￦ 8,466,000

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

US $ 9,600

￦ 12,600,000

폐암 검진 시장 : 유형별(저선량 CT(LDCT), X선), 연령층별(50세 이상, 50세 미만), 최종 사용자별(병원, 진단 센터, 기타) - 세계 기회 분석 및 산업 예측(2021-2031년)

Lung Cancer Screening Market By Type (Low-dose computed tomography (LDCT), X-ray), By Age group (50 and older, Below 50), By End User (Hospitals, Diagnostic Centers, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031

목차

제1장 소개

제2장 주요 요약

제3장 시장 개요

제4장 폐암 검진 시장 : 유형별

제5장 폐암 검진 시장 : 연령층별

제6장 폐암 검진 시장 : 최종 사용자별